PressNovember 21, 2022 Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial
PressNovember 18, 2022 atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
PressNovember 18, 2022 Silo Wellness Wins Amendment to Proposed Land Use Ordinance for Oregon Psychedelic Ranch; Corporate Update: Shareholder FAQs
PressNovember 18, 2022 Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York
PressNovember 18, 2022 Nova Mentis Enters into Research Contract with KGK Science for Phase II A Clinical Trial
PressNovember 17, 2022 Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
PressNovember 17, 2022 MAPS PBC Completes Second Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD
PressNovember 17, 2022 Filament Health Announces Psilocybin Supply Agreement With the Centre for Addiction and Mental Health
PressNovember 17, 2022 Albert Labs signs Letter of Intent (LOI) with iNGENū CRO for First In-Human Clinical Studies
PressNovember 16, 2022 Numinus to Host Q4 and Year End 2022 Results Conference Call on November 29, 2022
PressNovember 16, 2022 Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study
PressNovember 15, 2022 Field Trip Announces the Launch of Freedom by Field Trip™, a First-of-Its-Kind Ketamine Therapy Program
PressNovember 15, 2022 Beckley Psytech Successfully Completes Phase I Clinical Study of Lead Candidate BPL-003, a Novel Benzoate Formulation Of 5-MeO-DMT
PressNovember 15, 2022 Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
PressNovember 14, 2022 Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate
PressNovember 14, 2022 PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience
PressNovember 14, 2022 Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results
PressNovember 14, 2022 Revitalist and Wake Network Announce Joint Venture Partnership to Open Psychedelic Clinics and Retreats in the United States
